Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... from Concert's deuterium chemistry platform by replacing certain key hydrogen atoms of atazanavir with deuterium. In preclinical studies, the antiviral potency of...
2009 AUG 31 ... pharmacokinetic effects of coadministration of posaconazole (400 mg twice daily), with atazanavir (ATV) (300 mg/d alone) and with ritonavir (100 mg/d) or with efavirenz (400 mg/d) in ...
2009 AUG 31 ... tested by spiking Sno-strips ® with known concentrations of tenofovir, nevirapine, atazanavir, lopinavir, and ritonavir in blank cervicovaginal lavage fluid. Drug concentrations were ...
2009 AUG 17 ... Inc. (NASDAQ:MYL) and Matrix, a Mylan company, are making available all four drugs -- Atazanavir (ATV), Ritonavir (RTV), Tenofovir (TDF), and Lamivudine (3TC) -- needed to enable ...
2009 NOV 1 ... Fresh data on pharmacokinetics are presented in the report 'Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.' ...
2009 OCT 5 ... switching from a regimen including one protease inhibitor and one thymidine analogue to atazanavir/ritonavir plus abacavir/lamivudine or tenofovir/emtricitabine. Adult HIV-infected ...
2009 AUG 31 ... "HIV-1-infected adults receiving a regimen containing ritonavir-boosted atazanavir or fosamprenavir were recruited into a prospective study of adherence and dosage timing ...
2009 AUG 31 ... study "To assess the effectiveness and safety of antiretroviral therapy with unboosted atazanavir (400 mg once daily) plus co-formulated abacavir/lamivudine as a treatment simplification ...
2009 AUG 31 ... the United Kingdom report. "In addition, two new protease inhibitors, atazanavir and darunavir, which have activity against viruses resistant to other protease ...
2009 OCT 12 ... according to their hepatitis co-infection status after switching to ritonavir-boosted atazanavir (ATV/r)-based therapy. Rates of treatment discontinuation, changes in liver enzyme ...
2009 OCT 12 ... 100,000 copies/mL (70.9%) (p=0.0005). For the trials of lopinavir/ritonavir (LPV/r), atazanavir/ritonavir (ATV/r) and fosamprenavir/ritonavir (FAPV/r) using either TDF/FTC or ABC/3TC, ...
2009 SEP 14 ... the United States conducted a study "To quantify the pharmacokinetics of amprenavir and atazanavir (administered as the prodrug fosamprenavir) alone and in combination in human ...
2009 AUG 31 ... conducted a study "To study factors influencing lipid changes after switching to atazanavir (ATV) and the effectiveness of ATV in maintaining virus suppression. Retrospective ...
2009 SEP 28 ... in vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the infectious ...
2009 AUG 18 ... should be limited to 2.5 mg when coadministered with a strong CYP 3A4/5 inhibitor (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ...
Subject: Bristol-Myers Squibb Company and AstraZeneca
2009 AUG 17 ... should be limited to 2.5 mg when coadministered with a strong CYP 3A4/5 inhibitor (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ...
Subject: Bristol-Myers Squibb Company and AstraZeneca
